At Somahlution, we are serious about surrounding ourselves with intelligent, experienced professionals who can help us grow our business and improve our processes. Strong corporate governance is essential for a successful business, and our board members ensure Somahlution operates with integrity and accountability. We seek to build and maintain a Board of Directors with a wide range of experiences, competencies and perspectives and who help direct strategy, and can help us adapt to growing and changing markets, and geographic and regulatory environments.
Board of Directors
Dr. Dhaduk is the Chairman of the Board of Directors of Somahlution. He is an accomplished serial entrepreneur and serves as Chairman of several biotechnology companies, many of which he cofounded, including, Apicore Pharma, Synerex Pharmaceuticals, Nuron Biotech and Core Pharma.<br><br>Dr. Dhaduk provides leadership and guidance in the areas of product development, marketing, partner relationships, financial matters, and corporate governance. His extensive background in biotechnology and the pharmaceutical industry is an important asset to Somahlution’s development and business plans.<br><br>Dr. Dhaduk is an actively practicing neurologist and is currently the Chief of Neurology at the Community Medical Center in Scranton, PA and a Fellow of the American Academy of Neurology. His post-graduate medical training was conducted at the B.J. Medical College in Ahmedabad, India and at the Medical College of Pennsylvania in Philadelphia, where he also served as the Chief Resident in Neurology.<br><br>Dr. Dhaduk has received numerous honors in medical practice. Most notably, he received the David Dunn Memorial Award in 1986 and 1987 for Outstanding Teaching and Study of Neurology at the Medical College of Pennsylvania. He also serves on the board of several professional organizations in neurology and medicine. He is the chair of CARITAS International Trading and CARITAS Hospitality, LLC, on the advisory boards of Hope Medical Institute, Lublin College of Medicine, Poland, as well as the Lupus Foundation of Pennsylvania. He has been awarded the National Leadership Award serving as honorary co-chairman of the Physician’s Advisory Board, Pennsylvania.View More
Board of Directors, Executive Management Team
Dr. Chandran co-founded Somahlution with Chairman Dr. Dhaduk, and has served as the Company’s Chief Executive and a member of the Board of Directors since inception in 2010. He is a distinguished biotechnology veteran with nearly 25 years of leadership positions.<br><br>Until 2012, Dr. Chandran was the Director of the Center of Excellence for Biopharmaceutical Research & Development and Professor of Pharmaceutics at North Dakota State University. Prior to that, he was the Chief Technology Officer at the BioTx Division of Pfizer, in Cambridge. Previous to Pfizer, he was a Professor at the Institute for Hepatitis and Virus Research in Doylestown, PA, and was the Chief Operating Officer and Chief Scientific Officer at Nucleonics, the first RNAi-based company, in Horsham PA, a company that he cofounded while on the faculty at Thomas Jefferson University’s Biochemistry Department.<br><br>Prior to founding Nucleonics, Dr. Chandran led the DNA Vaccine Division of Wyeth-Lederle Vaccines following its 1998 acquisition of Apollon, Inc., a biotech company in Malvern, PA, focused on advancing DNA vaccine-based product candidates for infectious diseases and cancer.<br><br>Dr. Chandran received his Ph.D. from Memorial University in Newfoundland, Canada and completed a post-doctoral fellowship at Fox Chase Cancer Center in Philadelphia. He is a strategic consultant and a member of the Board of Directors for several emerging and established biotechnology companies.View More
Board of Directors, Executive Management Team
Dr. Pachuk joined Somahlution as its Chief Scientific Officer in August 2011 and is a member of the Company’s Board of Directors. She has twenty years of R&D leadership experience in the pharmaceutical and biotech sectors with expertise in drugs, biologics and vaccine development. She was involved in advancing multiple product candidates into the clinic.<br><br>Dr. Pachuk began her biotech career with Apollon, Inc. developing oligonucleotide-based therapeutics, and subsequently DNA-based vaccines for both viral and oncology indications. Following the acquisition of Apollon, Inc. by Wyeth-Lederle Vaccines in 1998 she continued to direct vaccine programs which resulted in several products being advanced into the clinic.<br><br>In 2001 she co-founded Nucleonics, a biotech focused on the development of RNAi-based therapeutics. Until April of 2008, she was VP of Preclinical Research. Since then and until joining Somahlution, Dr. Pachuk has lead biology efforts for Pfizer’s oligonucleotide therapeutic programs in the areas of oncology and metabolic disease and was a member of the Executive Leadership Team. <br><br>Dr. Pachuk received her Ph.D. in molecular virology from the University of Pennsylvania and completed a post-doctoral fellowship at SmithKline Beecham.View More